Elite Pharma Q2 Revenue Climbs 10% to $40.1M, Operating Income Up 21%
ELTP sits 16% above its 52-week low of $0.211 on light trading volume (0.3× avg).
Summary
Elite reported fiscal Q2 revenue of $40.1 million, up $3.8 million or about 10.4% year over year, driven by its Elite-label amphetamine and naltrexone lines. Operating income rose 21% to $9.9 million, and net income attributable to common shareholders was $17.3 million. The operating gain is notable because the six-month gross margin has compressed to 41% from 54%, so the quarterly operating improvement runs against a weaker first-half margin trend. Management also flagged material weaknesses in internal controls in the 10-Q filed today. The stock trades around $0.245 with a roughly $264 million market cap, so a $17.3 million quarterly profit is large relative to the equity base. Management hosts a conference call November 13 at 11:30 AM EST to discuss the quarter and recent business developments.
At the time of this announcement, ELTP was trading at $0.25 on OTC in the Life Sciences sector, with a market capitalization of approximately $263.9M. The 52-week trading range was $0.21 to $0.69. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.